The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Mylan N.V. (Nasdaq: MYL) ("Mylan" or the "Company") securities during the period between February 28, 2013 and October 7, 2016, inclusive (the "Class Period"). Investors who wish to become proactively involved in the litigation have until December 12, 2016 to seek appointment as lead plaintiff. If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Mylan securities during the Class Period. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action. The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants' failure to disclose during the Class Period that Mylan N.V. and Mylan Inc. incorrectly classified EpiPen as a generic drug under the Medicaid Drug Rebate Program, which reduced the amount of quarterly rebates Mylan N.V. and Mylan Inc. owed for EpiPen. According to the complaint, following a September 2, 2016 article stating that the Centers for Medicare & Medicaid Services ("CMS") informed Mylan that it incorrectly classified EpiPen as a generic, and an October 5, 2016 article regarding a letter issued by CMS, which stated that it had told Mylan that it classified EpiPen incorrectly, the value of Mylan N.V. shares declined significantly.